Please login to the form below

Is the world ready for a COVID-19 vaccine?

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.

By Shannon Lacombe, Hanover Health

At the beginning of the coronavirus pandemic, Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), dramatically told a G20 Leaders’ Summit that “we are at war with a virus that threatens to tear us apart.” At the same meeting, António Guterres, UN General Secretary, said “we are at war with a virus – and not winning it... this war needs a war-time plan to fight it”.

While there has been contention and debate about the appropriateness of the wartime analogy, it does seem to work to describe the unprecedented scale and effort required to sequester and defeat this virus. And while not military strategists, we can speculate that any “war-time plan” should be made up of a number of parts and that its success is reliant on the sum of those parts. In this case, a significant component is the successful development and roll out of a COVID-19 vaccine.

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection, based on initial results from their ongoing Phase 3 clinical trial. While the roll out of this vaccine still requires approvals by many national regulatory agencies, at the time of writing, both the UK and Canada had moved ahead with authorizations of the vaccine. Furthermore, the companies stated they could have as many as 50 million doses produced by the end of 2020 and 1.3 billion doses by the end of 2021. Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.

This is a phenomenal feat and one which would have been largely unimaginable just one year ago. Vaccines pass through multiple stages of development and in normal times, it wouldn’t be unusual for the process to take 10–15 years. In COVID-19 times, this process has taken less than 12 months.

It is one of the greatest breakthroughs in modern medicine to have developed a vaccine in this timescale. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges.

In the situation where the vaccine gets to everyone who would benefit from it, millions of doses will need to travel hundreds, if not thousands, of miles from manufacturers to hospitals, to general practices and pharmacies, which in turn must store, track and eventually administer the vaccines. This isn’t completely new territory; organisations such as the Centers for Disease Control and Prevention (CDC) in the United States, which distributed flu vaccines during the 2009 H1N1 pandemic with the help of local organisations, manage the roll out of routine immunisations every day.

A few of the coronavirus vaccines being trialled use “messenger” RNA (mRNA) technology. While this novel vaccine technology has never received approval before, it looks like it may be one of a few optimal and innovative immunisation approaches. After injection into muscle, the synthetic mRNA is taken up by cells and the cell’s machinery reads it to make a surface protein of the SARS-CoV-2 virus, called the “spike protein”. The rest of the process is identical to that used by other vaccines, where the immune system mounts a response by recognising the viral protein as foreign and develops antibodies against it.

One of the reasons these vaccines have progressed so quickly to, and through, clinical trials is because they are the fastest to make and manufacture. Within weeks, clinical batches can be generated through a process that is cell-free and scalable. However, on the flip side, these vaccines may also be the slowest or most difficult to deploy. While they rely on a technology whose central advantage hinges on rapidity of manufacture, its downfall is extreme physical fragility.

These first mRNA vaccines must be frozen at extremely low temperatures, and once thawed, will stay intact for only a short period of time. Furthermore, these vaccines must be given in two separate doses, administered weeks apart and both doses must come from the same manufacturer. This means that vaccine administration will require careful record tracing and tracking, which may be less of a challenge in a single-payer health system, but poses a whole set of challenges for countries and states that do not have immunisation registries or ways of tracking patients. In time, some of these challenges may be overcome, for example, if the technology used for mRNA vaccines advances to allow them to be stored at higher temperatures. However, the novelty of these vaccines means that even the manufacturers are still figuring out these challenges.

Another, and perhaps grander, challenge is one of global vaccine equity and reducing inequalities in access. One of the ways the world is looking to mitigate this is through the COVAX initiative, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Alliance for Vaccines and Immunisation (GAVI) and the WHO. COVAX is a multinational collaborative platform that is supporting the research, development and manufacturing of a wide range of COVID-19 vaccine candidates. All participating countries, regardless of income levels, will have equal access to these vaccines once they are developed. The initial aim is to have 2 billion doses available by the end of 2021, which should be enough to protect high-risk and vulnerable people, as well as frontline healthcare workers. Without the successful implementation of COVAX, there is a very real risk that the majority of people in the world would go unprotected against COVID-19 and the pandemic would continue to wreak havoc.

To have a truly effective prevention approach, first we need COVID-19 vaccines that are both safe and effective; we then need these to be manufactured at scale; and finally, we need them to be deployed effectively and to all corners of the world. Of course, another key piece of an effective vaccination roll-out is being able to communicate to the public about all of these aspects of a complicated topic.

The above is not an exhaustive list but should illustrate that this is not going to be a straightforward exercise. While a lot of the messaging around ending the pandemic has been reliant on the success of a vaccine, this does not mean that once a vaccine has arrived, the pandemic is over. There are still a lot of kinks to work out and a lot of challenges to overcome. The development of an effective vaccine remains truly a phenomenal feat, but it is only step one, and the healthcare industry would be doing the world a disservice if it did not acknowledge that.

It is also critical to understand that a vaccine is not the only piece to the pandemic puzzle. Whilst it remains one of the components (albeit a key one), there are other key components, including effective therapeutics and lifestyle interventions – all of which will play their part in our success.

There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Where one vaccine may be more stable and easier to store, another may be more effective in older people, and another may require fewer doses. We are on the cusp of modern medicine’s most impressive influx of innovation and the first wave of vaccines are certainly not going to be the only important ones.

To end with the contentious war-time analogy – we may be well on our way to winning this battle, but we are still fighting a war. All of us—across industry, advocacy organisations and policymakers—have some more time ahead of us in the trenches before we can claim ourselves victorious.

As companies continue to publish positive results from vaccine trials, it will be critical for the pharmaceutical sector, advocacy organisations, and decision makers, to consider how to ensure all of those that will benefit most urgently from a vaccine, receive it. As healthcare policy specialists, we must work to support organisations and stakeholders during this time to navigate a complex and evolving landscape.

To further explore how we can support companies and advocacy partners during this complex time, please contact us.

18th December 2020

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

What next for health? The weeks that have seen a whirlwind in Whitehall.
It won’t have escaped your attention that the debris from the PM’s recent reshuffle has left industry and policy makers with more questions than it has answers. This comes at a critical time for the healthcare system, particularly ahead of the winter period. ‘Levelling Up’ is the agenda. Covid has highlighted the extent of health inequalities across the UK. In her latest blog, Ursula Ritz considers the implications of the change of senior leadership at DHSC and NHSE for existing priorities, including for those of us committed to ensuring the best and innovative drugs make it to patients.
Press Releases
Will most electronic consumer goods turn into medical devices after the MDR?
In her latest blog, Hanover Brussels Aleksandra Lugovic explores concerns over the rising coexistence of health apps and electronic goods that may become medical devices according to the EU Regulation.
Hanover Communications
What do NHS changes and the Life Sciences Vision mean for medicines?
With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.
Hanover Communications
Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Hanover Communications
Greener healthcare - a shared challenge
At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.
Hanover Communications
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications